This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Immunomedics to be Acquired by Gilead for About 21 Billion
by Zacks Equity Research
Immunomedics Inc. (IMMU) will be acquired by Gilead (GILD) for about $21 billion.
Bayer Collaborates With Recursion for Fibrotic Diseases
by Zacks Equity Research
Bayer (BAYRY) inks deal with Recursion Pharmaceuticals for the treatment of fibrotic diseases.
Catalyst (CPRX) Eyes Firdapse Label Expansion Amid Competition
by Zacks Equity Research
Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of concern.
Gilead Submits sBLA to FDA for CAR-T in Non-Hodgkin Lymphomas
by Zacks Equity Research
Gilead submits a supplemental Biologics License Application to the FDA for Yescarta for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.
Horizon Therapeutics' Stock Rises YTD on Approvals & Buyouts
by Zacks Equity Research
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. It is making efforts to expand the label for its marketed drugs.
Sesen Bio (SESN) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
Sesen Bio (SESN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Alexion (ALXN) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
Alexion (ALXN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Reasons to Invest in Dr. Reddy's (RDY) Amid Coronavirus Woes
by Zacks Equity Research
Dr. Reddy's (RDY) continues to make products launches despite tepid sales volumes due to the COVID-19 pandemic.
5 Reasons to Invest in Horizon Therapeutics Amid Coronavirus
by Zacks Equity Research
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. The company's efforts to develop its pipeline are impressive.
Syros (SYRS) in Focus: Stock Moves 7.9% Higher
by Zacks Equity Research
Syros (SYRS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Agenus (AGEN) in Focus: Stock Moves 7.6% Higher
by Zacks Equity Research
Agenus (AGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Intercept (ICPT) Catches Eye: Stock Jumps 8.4%
by Zacks Equity Research
Intercept (ICPT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Earnings Preview: Techne (TECH) Q4 Earnings Expected to Decline
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Techne (TECH) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Techne (TECH) could produce exceptional returns because of its solid growth attributes.
REGN vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. TECH: Which Stock Is the Better Value Option?
LGND or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. TECH: Which Stock Is the Better Value Option?
LGND vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LGND vs. TECH: Which Stock Is the Better Value Option?
Techne (TECH) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 23.01% and 5.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Techne (TECH) Q3 Earnings Expected to Decline
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
REGN vs. TECH: Which Stock Is the Better Value Option?
Techne (TECH) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -5.26% and -3.50%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GILD vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. TECH: Which Stock Is the Better Value Option?
CELG vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
CELG vs. TECH: Which Stock Is the Better Value Option?
Techne (TECH) Q1 Earnings Lag Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -0.93% and 1.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?